Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market

ABOUT THIS REPORT
- Market Snapshot
- Market Overview
- Scope of the report
- Key Market Trends
- Competitive Landscape
- Major Players
TABLE OF CONTENTS

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

CAGR:

7.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors that are responsible for the growth of the market includes growing burden of ovarian cancer and use of combination therapies for the treatment of ovarian cancer. The incidences of ovarian cancer are high in women aged 55-64 years. The major symptoms of ovarian cancer include bloating, pelvic and abdominal pain, difficulty in eating, and urinary symptoms. According to Globocan, in 2018, there were around 1,371 new ovarian cancer cases in South Africa and around 971 people died due to this disease. However, the others factors, such as lack of awareness in emerging and low income economies are expected to impede the market growth.

Scope of the report

As per the scope of the report, Ovarian cancer is a type of cancer that begins in the ovaries. There are several types of ovarian cancer, Epithelial ovarian cancer is the most common type of ovarian cancer. Ovarian cancer is caused by uncontrollable cell growth in the ovarian tissue. It is a growing concern and one of the most common causes of death in women.

By Cancer Type
		Epithelial Ovarian Tumors
		Ovarian Germ Cell Tumors
		Others

By Modality

Diagnosis
	Biopsy
	Blood Tests
	Ultrasound
	PET
	CT Scan
	Other Diagnosis

Therapeutics
	Chemotherapy
	Radiation Therapy
	Immunotherapy
	Hormonal Therapy
	Others

Geography

Middle-East and Africa
	GCC
	South Africa
	Rest of Middle-East and Africa

Report scope can be customized per your requirements. Click here.

Key Market Trends

CT Scan Segment is Expected to Show Better Growth in the Forecast Period

Computed Tomography (CT) is an imaging procedure that uses special X-ray equipment to create detailed pictures, or scans, of areas inside the body. It is also called computerized tomography and computerized axial tomography (CAT). This equipment does not show small ovarian tumors well, but they can see larger tumors, and may be able to see if the tumor is growing into nearby structures. It can also find the enlarged lymph nodes, signs of cancer spread to the liver or other organs, or signs that an ovarian tumor is affecting the kidneys or bladder. Furthermore, with the rising burden of ovarian cancer and technological advancements is expected to fuel the market growth over the forecast period.

To understand key trends, Download Sample Report

Competitive Landscape

The majority of ovarian cancer diagnostics and therapeutics products is being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. This has helped the market grow.

Major Players

You can also purchase parts of this report. Do you want to check out a section wise price list?

1. INTRODUCTION
1. 1.1 Study Deliverables
2. 1.2 Study Assumptions
3. 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. 4.1 Market Overview
2. 4.2 Market Drivers
  1. 4.2.1 Growing Burden of Ovarian Cancer
  2. 4.2.2 Use of Combination Therapies for the Treatment of Ovarian Cancer
3. 4.3 Market Restraints
  1. 4.3.1 Lack of Awareness in Emerging and Low Income Economies
4. 4.4 Porter's Five Forces Analysis
  1. 4.4.1 Threat of New Entrants
  2. 4.4.2 Bargaining Power of Buyers/Consumers
  3. 4.4.3 Bargaining Power of Suppliers
  4. 4.4.4 Threat of Substitute Products
  5. 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. 5.1 By Cancer Type
  1. 5.1.1 Epithelial Ovarian Tumors
  2. 5.1.2 Ovarian Germ Cell Tumors
  3. 5.1.3 Others
2. 5.2 By Modality
  1. 5.2.1 Diagnosis
    1. 5.2.1.1 Biopsy
    2. 5.2.1.2 Blood Tests
    3. 5.2.1.3 Ultrasound
    4. 5.2.1.4 PET
    5. 5.2.1.5 CT Scan
    6. 5.2.1.6 Other Diagnosis
  2. 5.2.2 Therapeutics
    1. 5.2.2.1 Chemotherapy
    2. 5.2.2.2 Radiation Therapy
    3. 5.2.2.3 Immunotherapy
    4. 5.2.2.4 Hormonal Therapy
    5. 5.2.2.5 Others
3. 5.3 Geography
  1. 5.3.1 Middle-East and Africa
    1. 5.3.1.1 GCC
    2. 5.3.1.2 South Africa
    3. 5.3.1.3 Rest of Middle-East and Africa
6. COMPETITIVE LANDSCAPE
1. 6.1 Company Profiles
  1. 6.1.1 Astrazeneca plc
  2. 6.1.2 Bristol Myers Squibb Company
  3. 6.1.3 Eli Lilly and Company
  4. 6.1.4 F. Hoffman-La Roche Ltd
  5. 6.1.5 Glaxosmithkline Plc
  6. 6.1.6 Johnson and Johnson (Janssen Pharmaceuticals)
  7. 6.1.7 Pfizer Inc.
  8. 6.1.8 Siemens Healthineers AG

*List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments